Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases

Core Insights - Kiora Pharmaceuticals reported its third quarter 2025 financial results and provided updates on its clinical pipeline for retinal diseases, highlighting the advancement of two actively enrolling Phase 2 clinical trials [1][2]. Clinical Trials Update - The company is actively recruiting participants for two Phase 2 clinical trials: ABACUS-2 for KIO-301 aimed at vision restoration in retinitis pigmentosa, and KLARITY for KIO-104 targeting retinal inflammation [2][5]. - The ABACUS-2 trial has expanded its screening and enrollment to include patients from a functional endpoint validation study, potentially increasing the patient population for KIO-301 [2][3]. - KLARITY is designed as a two-stage, multi-dose study focusing on patients with inflammatory retinal diseases causing macular edema, with a pre-defined safety assessment [3]. Financial Highlights - Kiora received $1.2 million in reimbursed R&D expenses from Théa for KIO-301 activities in Q2 2025 and billed $1.5 million in Q3 2025, with $0.3 million received in the same quarter [5][6]. - The company ended Q3 2025 with $19.4 million in cash, cash equivalents, and short-term investments, alongside $1.2 million in collaboration receivables and $1.5 million in tax and research credit receivables [5][6]. - Kiora's cash runway is projected to extend into late 2027, beyond anticipated data readouts for both clinical trials, with potential for further extension through partnership milestones [6]. R&D and Operating Expenses - R&D expenses for Q3 2025 were $2.7 million, an increase from $2.1 million in Q3 2024, primarily due to clinical trial activities [7]. - General and administrative expenses remained stable at $1.4 million for both Q3 2025 and Q3 2024 [7]. Income Statement Overview - Kiora reported a net income of $27 thousand for Q3 2025, a significant improvement from a net loss of $3.4 million in Q3 2024, attributed to favorable tax impacts and control of operating costs [8][14]. - The company recorded total revenue of $16 million for the nine months ended September 30, 2024, primarily from collaboration revenue [14]. Company Profile - Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for retinal diseases using innovative small molecules [9]. - KIO-301 is being developed for retinitis pigmentosa, with plans to expand into other retinal diseases, while KIO-104 targets retinal inflammation [9].